Sonja Krausert

TL;DR: BA 1436032 has been shown to significantly prolong survival of mice intracerebrally transplanted with human astrocytoma carrying the IDH1R132H mutation and is developed a pan-inhibitor targeting tumors with different IDH 1R132 mutations.

TL;DR: It is shown that R-loop-associated chromosomal instability can be induced by the loss of DICER1 function, and targeting R-loops with topoisomerase and PARP inhibitors might be an effective treatment strategy for this deadly disease.

TL;DR: The first human SMO inhibitor resistant medulloblastoma PDX models are reported, which can be used for further preclinical experiments to develop the best strategies to overcome the resistance to SMO inhibitors in patients.

TL;DR: Investigation of other pediatric brain tumor types with high levels of R-loops and in vitro drug screens found PARP inhibitors were identified as the most synergistic combination partners for the topoisomerase inhibitor Irinotecan and the active metabolite SN-38, but normal Astrocytes were not sensitive to these combinations.

TL;DR: Establishment and characterization of pediatric brain tumor models in an orthotopic mouse model and molecular and phenotypic characterization of the transduced vs the un-transduced PDX will increase the utility of this platform for the development of new drugs and the identification of innovative drug targets.